Gabapentin Capsule
Product Images NDC 68788-8199

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8199). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules 100mg (6ecf5114 2ddc 4025 A36d 1884702dc22a 00)

This is a description of Gabapentin Capsules 100mg, a medication used for treatment of several conditions, including seizures and nerve damage. The drug is available in capsule form, with each capsule containing 100mg of Gabapentin. The packaging information reveals the expiration date, the lot number, as well as the manufacturer's details. It is important to note that transferring this medication to anyone other than the person for whom it was prescribed is prohibited by federal law. The packaging also advises keeping this medication out of reach for children. It's unclear what "Billing Chart Log" refers to.*

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

This formula calculates the estimated creatinine clearance (ClCr) for patients based on their age, weight, and serum creatinine levels. The formula is adjusted for female patients by multiplying the result by 0.85.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

This appears to be a table or chart showing a 4 week fixed dose period with three different treatments: placebo, Gabapentin at 1800 mg/day, and Gabapentin at 2400 mg/day. The chart also includes a "mean pain score" measured at baseline and weeks 1 through 7. Without more information, it is unclear what condition or population this data pertains to.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

The text describes a figure (Figure 3) showing the percentage of patients with a greater than 50% reduction in pain score (responders) in studies evaluating the effectiveness of a medication for controlled PHN (Postherpetic neuralgia). The text provides the percentages for two studies (Study 1 and Study 2) and shows that Study 2 had higher response rates compared to Study 1. There is also a reference to a statistical significance (p<0.001) and the cost of the medication (GBP 800 and GBP 2400).*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.